US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

JNCE

Jounce Therapeutics (JNCE)

Jounce Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:JNCE

1 2 3 4 5 6 7 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
14/02/2024	07:50	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:JNCE	Jounce Therapeutics Inc
15/05/2023	06:41	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:JNCE	Jounce Therapeutics Inc
05/05/2023	15:38	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:JNCE	Jounce Therapeutics Inc
05/05/2023	15:35	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:JNCE	Jounce Therapeutics Inc
05/05/2023	05:09	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:JNCE	Jounce Therapeutics Inc
04/05/2023	07:40	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	NASDAQ:JNCE	Jounce Therapeutics Inc
04/05/2023	06:31	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:JNCE	Jounce Therapeutics Inc
04/05/2023	06:25	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:JNCE	Jounce Therapeutics Inc
04/05/2023	06:23	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:JNCE	Jounce Therapeutics Inc
04/05/2023	06:08	Edgar (US Regulatory)	Amended Statement of Ownership: Solicitation (sc 14d9/a)	NASDAQ:JNCE	Jounce Therapeutics Inc
03/05/2023	19:35	GlobeNewswire Inc.	Jounce Therapeutics Announces Closing of Tender Offer	NASDAQ:JNCE	Jounce Therapeutics Inc
28/04/2023	13:48	Edgar (US Regulatory)	Amended Annual Report (10-k/a)	NASDAQ:JNCE	Jounce Therapeutics Inc
03/04/2023	06:55	Edgar (US Regulatory)	Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)	NASDAQ:JNCE	Jounce Therapeutics Inc
03/04/2023	01:00	GlobeNewswire Inc.	Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc	NASDAQ:JNCE	Jounce Therapeutics Inc
27/03/2023	13:12	Edgar (US Regulatory)	Statement of Ownership: Solicitation (sc 14d9)	NASDAQ:JNCE	Jounce Therapeutics Inc
27/03/2023	08:00	GlobeNewswire Inc.	Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights	NASDAQ:JNCE	Jounce Therapeutics Inc
16/03/2023	15:30	GlobeNewswire Inc.	Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer	NASDAQ:JNCE	Jounce Therapeutics Inc
14/03/2023	20:00	GlobeNewswire Inc.	Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences	NASDAQ:JNCE	Jounce Therapeutics Inc
14/03/2023	16:01	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:JNCE	Jounce Therapeutics Inc
10/03/2023	08:24	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:JNCE	Jounce Therapeutics Inc
06/03/2023	15:00	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:JNCE	Jounce Therapeutics Inc
23/02/2023	15:56	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:JNCE	Jounce Therapeutics Inc
23/02/2023	01:30	GlobeNewswire Inc.	Redx and Jounce Announce Recommended Business Combination	NASDAQ:JNCE	Jounce Therapeutics Inc
22/02/2023	16:00	GlobeNewswire Inc.	Jounce Therapeutics Announces Restructuring	NASDAQ:JNCE	Jounce Therapeutics Inc
14/02/2023	15:55	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:JNCE	Jounce Therapeutics Inc
09/01/2023	05:02	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NASDAQ:JNCE	Jounce Therapeutics Inc
27/12/2022	16:24	Dow Jones News	Gilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce Therapeutics	NASDAQ:JNCE	Jounce Therapeutics Inc
27/12/2022	15:30	Business Wire	Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics	NASDAQ:JNCE	Jounce Therapeutics Inc
27/12/2022	15:30	GlobeNewswire Inc.	Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics	NASDAQ:JNCE	Jounce Therapeutics Inc
08/12/2022	06:50	GlobeNewswire Inc.	Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress	NASDAQ:JNCE	Jounce Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:JNCE

1 2 3 4 5 6 7 Próxima >

Health Care Select Sector

Financial Select Sector

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones